Page last updated: 2024-11-05

thalidomide and Fibromatosis, Aggressive

thalidomide has been researched along with Fibromatosis, Aggressive in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Fibromatosis, Aggressive: A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, X1
Wang, H1
Wu, X1
Hong, X1
Luo, Z1

Trials

1 trial available for thalidomide and Fibromatosis, Aggressive

ArticleYear
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.
    Investigational new drugs, 2018, Volume: 36, Issue:1

    Topics: Adult; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

2018